{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:54:25Z","timestamp":1784145265365,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD003865"],"award-info":[{"award-number":["U01FD003865"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40271-016-0164-1","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T10:02:42Z","timestamp":1459159362000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Development of a Symptom-Based Patient-Reported Outcome Instrument for Functional Dyspepsia: A Preliminary Conceptual Model and an Evaluation of the Adequacy of Existing Instruments"],"prefix":"10.1007","volume":"9","author":[{"given":"Fiona","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Reasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn T.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Iovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Jason","family":"Lundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah","family":"Pompilus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra G.","family":"Silberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"key":"164_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrgastro.2013.14","volume":"10","author":"J Tack","year":"2013","unstructured":"Tack J, Talley NJ. Functional dyspepsia\u2013symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol. 2013;10:134\u201341.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"164_CR2","unstructured":"Rome Foundation. Rome IV. 2013. \n                    http:\/\/www.romecriteria.org\/romeiv_pub\/index.cfm\n                    \n                  . Accessed 19 Jun 2014."},{"key":"164_CR3","first-page":"885","volume-title":"Rome III The functional Gastrointestinal Disorders","author":"DA Drossman","year":"2006","unstructured":"Drossman DA, Corazziari E, Delvaux M, et al. Appendix A: Rome III Diagnostic Criteria for FGIDs. In: Drossman DA, Corazziari E, Delvaux M, et al., editors. Rome III The functional Gastrointestinal Disorders. 3rd ed. McLean: Degnon Associates, Inc.; 2006. p. 885\u201397.","edition":"3"},{"key":"164_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/clpt.2011.203","volume":"90","author":"SJ Coons","year":"2011","unstructured":"Coons SJ, Kothari S, Monz BU, Burke LB. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims. Clin Pharmacol Ther. 2011;90:743\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"164_CR5","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009."},{"key":"164_CR6","unstructured":"U.S. Food and Drug Administration. Drug Development Tools (DDT) Qualification Programs. 2015. \n                    http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/default.htm\n                    \n                  . Accessed 22 Feb 2016."},{"key":"164_CR7","unstructured":"PROQOLID: Patient-Reported Outcome and Quality of Life Instruments Database. 2010. \n                    http:\/\/www.proqolid.org\/\n                    \n                  . Accessed 3 Apr 2012."},{"key":"164_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59\u201365.","journal-title":"JAMA"},{"key":"164_CR9","first-page":"69","volume":"15","author":"AL Shields","year":"2006","unstructured":"Shields AL, Gwaltney C, Tiplady B, et al. Grasping the FDA\u2019s PRO Guidance: what the agency requires to support the selection of patient reported outcome instruments. Applied Clinical Trials. 2006;15:69\u201377.","journal-title":"Applied Clinical Trials"},{"key":"164_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF03256856","volume":"25","author":"P Marquis","year":"2011","unstructured":"Marquis P, Caron M, Emery M, et al. The role of health-related quality of life data in the drug approval processes in the US and Europe. Pharm Med. 2011;25:147\u201360.","journal-title":"Pharm Med"},{"key":"164_CR11","unstructured":"U.S. Food and Drug Administration. Clinical Outcome Assessment (COA): Frequently asked questions. 2014. \n                    http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/ucm370261.htm\n                    \n                  . Accessed 6 Jun 2015."},{"key":"164_CR12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u201320.","journal-title":"Am J Gastroenterol"},{"key":"164_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cgh.2008.09.007","volume":"7","author":"AN Pilichiewicz","year":"2009","unstructured":"Pilichiewicz AN, Horowitz M, Holtmann GJ, et al. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2009;7:317\u201322.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"164_CR14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1023\/A:1005558204440","volume":"45","author":"NK Leidy","year":"2000","unstructured":"Leidy NK, Farup C, Rentz AM, et al. Patient-based assessment in dyspepsia: development and validation of dyspepsia symptom severity index (DSSI). Dig Dis Sci. 2000;45:1172\u20139.","journal-title":"Dig Dis Sci"},{"key":"164_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01535722","volume":"33","author":"J Svedlund","year":"1988","unstructured":"Svedlund J, Sjodin I, Dotevall G. GSRS\u2013a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129\u201334.","journal-title":"Dig Dis Sci"},{"key":"164_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/00365529309098272","volume":"28","author":"E Dimenas","year":"1993","unstructured":"Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681\u20137.","journal-title":"Scand J Gastroenterol"},{"key":"164_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2036.2005.02572.x","volume":"22","author":"B Adam","year":"2005","unstructured":"Adam B, Liebregts T, Saadat-Gilani K, et al. Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005;22:357\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"164_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/00042737-199610000-00006","volume":"8","author":"EM El-Omar","year":"1996","unstructured":"El-Omar EM, Banerjee S, Wirz A, McColl KE. The Glasgow Dyspepsia Severity Score\u2013a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol. 1996;8:967\u201371.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"164_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2036.2006.02774.x","volume":"23","author":"SJ Veldhuyzen van Zanten","year":"2006","unstructured":"Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther. 2006;23:521\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"164_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1046\/j.1440-1746.2002.02713.x","volume":"17","author":"WH Hu","year":"2002","unstructured":"Hu WH, Lam KF, Wong YH, et al. The Hong Kong Index of Dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia. J Gastroenterol Hepatol. 2002;17:545\u201351.","journal-title":"J Gastroenterol Hepatol"},{"key":"164_CR21","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1046\/j.1365-2036.1998.00404.x","volume":"12","author":"P Moayyedi","year":"1998","unstructured":"Moayyedi P, Duffett S, Braunholtz D, et al. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther. 1998;12:1257\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"164_CR22","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1111\/j.1572-0241.1999.01363.x","volume":"94","author":"NJ Talley","year":"1999","unstructured":"Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol. 1999;94:2390\u20137.","journal-title":"Am J Gastroenterol"},{"key":"164_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.7326\/0003-4819-111-8-671","volume":"111","author":"NJ Talley","year":"1989","unstructured":"Talley NJ, Phillips SF, Melton J III, et al. A patient questionnaire to identify bowel disease. Ann Intern Med. 1989;111:671\u20134.","journal-title":"Ann Intern Med"},{"key":"164_CR24","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11136-004-9567-x","volume":"13","author":"AM Rentz","year":"2004","unstructured":"Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737\u201349.","journal-title":"Qual Life Res"},{"key":"164_CR25","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s10620-004-9578-z","volume":"49","author":"GB Sander","year":"2004","unstructured":"Sander GB, Mazzoleni LE, Francesconi CF, et al. Development and validation of a cross-cultural questionnaire to evaluate nonulcer dyspepsia: the Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ). Dig Dis Sci. 2004;49:1822\u20139.","journal-title":"Dig Dis Sci"},{"key":"164_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-7525-6-31","volume":"6","author":"M Shaw","year":"2008","unstructured":"Shaw M, Dent J, Beebe T, et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008;6:31.","journal-title":"Health Qual Life Outcomes"},{"key":"164_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0895-4356(97)00245-X","volume":"51","author":"DH Kuykendall","year":"1998","unstructured":"Kuykendall DH, Rabeneck L, Campbell CJ, Wray NP. Dyspepsia: how should we measure it? J Clin Epidemiol. 1998;51:99\u2013106.","journal-title":"J Clin Epidemiol"},{"key":"164_CR28","doi-asserted-by":"crossref","unstructured":"Rabeneck L. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. Rheumatology (Oxford) 2003;42(Suppl 3):iii32\u20139.","DOI":"10.1093\/rheumatology\/keg496"},{"key":"164_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2036.2006.03233.x","volume":"25","author":"A Fraser","year":"2007","unstructured":"Fraser A, Delaney BC, Ford AC, et al. The Short-Form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther. 2007;25:477\u201386.","journal-title":"Aliment Pharmacol Ther"},{"key":"164_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1053\/j.gastro.2011.05.003","volume":"141","author":"F Zeng","year":"2011","unstructured":"Zeng F, Qin W, Liang F, et al. Abnormal resting brain activity in patients with functional dyspepsia is related to symptom severity. Gastroenterology. 2011;141:499\u2013506.","journal-title":"Gastroenterology"},{"key":"164_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-12-18","volume":"12","author":"MC Gawlicki","year":"2014","unstructured":"Gawlicki MC, McKown SM, Talbert MJ, Brandt BA. Application of Bother in patient reported outcomes instruments across cultures. Health Qual Life Outcomes. 2014;12:18.","journal-title":"Health Qual Life Outcomes"},{"key":"164_CR32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2036.2010.04566.x","volume":"33","author":"D Ang","year":"2011","unstructured":"Ang D, Talley NJ, Simren M, et al. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther. 2011;33:634\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"164_CR33","unstructured":"U.S. Department of Commerce, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. 2014."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-016-0164-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-016-0164-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-016-0164-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-016-0164-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:52:01Z","timestamp":1589669521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-016-0164-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1007\/s40271-016-0164-1","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,28]]},"assertion":[{"value":"28 March 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all aspects of manuscript development. Fiona Taylor participated in planning and executing the study, analyzing and interpreting the data, and drafting the manuscript; Catherine Foley and Farrah Pompilus participated in planning and executing the study, collecting, analyzing and interpreting the data, and drafting the manuscript; Ramon Iovin participated in collecting, analyzing, and interpreting the data and drafting the manuscript; Alan L. Shields participated in planning and executing the study, interpreting the data, and drafting the manuscript; David S. Reasner provided input on the study design and drafting of the manuscript; Robyn T. Carson, Linda S. Deal, Debra G. Silberg, and Jason Lundy provided input on the study design and manuscript.FT, CF, and ALS are employees of Adelphi Values, which received payment from the sponsors to conduct the research; RI and FP were employees of Adelphi Values at the time this research was conducted. DSR is a member of Albemarle Scientific Consulting and an employee of Ironwood Pharmaceuticals, and owns stock and stock options in Ironwood. RTC is an employee of Allergan and owns stock and stock options in Allergan. At the time of the research, LSD and DGS were employees of Shire, and have shareholdings in Shire and other pharmaceutical companies through stocks and mutual funds. JJL was an employee of the Critical Path Institute at the time this research was conducted. Any views expressed in this publication represent the personal opinions of the authors, not those of their respective employer. The authors\u2019 respective organizations were given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}